SLC25A6 and osteosarcoma: Similarly, studies have demonstrated that EFHD1 inhibits mPTP opening and enhances mitochondrial function through SLC25A6, reducing mitochondrial Cyt c release and promoting the proliferation and chemoresistance in osteosarcoma [47].